Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...

BRISBANE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated ...

Figures released by the Global Cancer Observatory (Globocan) in 2020 show that ... a presidential initiative to screen for Hepatocellular Carcinoma (HCC), the most common type of liver cancer ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Announcing a new publication for Acta Materia Medica journal. Icaritin (ICA) is a prenylflavonoid natural product extracted from plants of the Epimedium genus.

This study investigated the long-term prognosis and clinical course of patients who survived for more than 5 years after hepatocellular carcinoma (HCC) diagnosis.This retrospective cohort study used ...

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have ...

On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...